%0 Case Reports
%T Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis.
%A Colapietro F
%A Pugliese N
%A Voza A
%A Aghemo A
%A De Nicola S
%J World J Gastroenterol
%V 30
%N 9
%D 2024 Mar 7
%M 38577192
%F 5.374
%R 10.3748/wjg.v30.i9.1253
%X Hepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient's underlying tumor and the specific malignancy type (solid or hematologic) plays a crucial role and needs to be assessed for decision-making process.